NCT05821894 Atherosclerotic Plaque Imaging Project (CPIP)
| NCT ID | NCT05821894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lund University |
| Condition | Atherosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2005-10-26 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 2005-10-26 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.
Eligibility Criteria
Inclusion Criteria: * Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent. Exclusion Criteria: * Patients younger than 18 years old that cannot provide informed consent; pregnant.
Contact & Investigator
Isabel Goncalves, MD, PhD
PRINCIPAL INVESTIGATOR
Lund University
Frequently Asked Questions
Who can join the NCT05821894 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05821894 currently recruiting?
Yes, NCT05821894 is actively recruiting participants. Contact the research team at Isabel.Goncalves@med.lu.se for enrollment information.
Where is the NCT05821894 trial being conducted?
This trial is being conducted at Malmö, Sweden.
Who is sponsoring the NCT05821894 clinical trial?
NCT05821894 is sponsored by Lund University. The principal investigator is Isabel Goncalves, MD, PhD at Lund University. The trial plans to enroll 3,500 participants.